Search results
Found 30540 matches for
Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.
MSD Mediation Service
Building better workplace relationships and equipping people to manage conflict better.
New theory for spontaneous reporting of suspected adverse drug reactions to biological therapies
Adverse drug reactions, commonly known as side effects, place a significant burden on health services and account for patient deaths, disease, and extra costs in the UK and worldwide. This research is about the reporting of side effects of biologic medicines on patients.
UK Human Functional Genomics Initiative: Musculoskeletal Cluster
Our research will use genetics to improve our understanding and treatment of musculoskeletal diseases, such as osteoarthritis and carpal tunnel syndrome, which cause more years of disability and pain than any other disease class.
2022-2024 cohort
Find out about our 2022-2024 alumni.